Absorptive-mediated Endocytosis of Cationized Albumin and a Beta-endorphin-cationized Albumin Chimeric Peptide by Isolated Brain Capillaries. Model System of Blood-brain Barrier Transport
Overview
Authors
Affiliations
Cationized albumin (pI greater than 8), unlike native albumin (pI approximately 4), enters cerebrospinal fluid (CSF) rapidly from blood. This suggests that a specific uptake mechanism for cationized albumin may exist at the brain capillary wall, i.e. the blood-brain barrier. Isolated bovine brain capillaries rapidly bound cationized [3H]albumin and approximately 70% of the bound radioactivity was resistant to mild acid wash, which is assumed to represent internalized peptide. Binding was saturable and a Scatchard plot gave a maximal binding capacity (Ro) = 5.5 +/- 0.7 micrograms/mgp (79 +/- 10 pmol/mgp), and a half-saturation constant (KD) = 55 +/- 8 micrograms/ml (0.8 +/- 0.1 microM). The binding of cationized [3H]albumin (pI = 8.5-9) was inhibited by protamine, protamine sulfate, and polylysine (molecular weight = 70,000) with a Ki of approximately 3 micrograms/ml for all three proteins. The use of cationized albumin in directed delivery of peptides through the blood-brain barrier was examined by coupling [3H]beta-endorphin to unlabeled cationized albumin (pI = 8.5-9) using the bifunctional reagent, N-succinimidyl 3-(2-pyridyldithio)proprionate. The [3H]beta-endorphin-cationized albumin chimeric peptide was rapidly bound and endocytosed by isolated bovine brain capillaries, and this was inhibited by unlabeled cationized albumin but not by unconjugated beta-endorphin or native bovine albumin. Cationized albumin provides a new tool for studying absorptive-mediated endocytosis at the brain capillary and may also provide a vehicle for directed drug delivery through the blood-brain barrier.
Drug delivery strategies with lipid-based nanoparticles for Alzheimer's disease treatment.
Jang Y, Kang S, Park H, Lee D, Kim J, Kim J J Nanobiotechnology. 2025; 23(1):99.
PMID: 39930497 PMC: 11809104. DOI: 10.1186/s12951-025-03109-3.
Schwinghamer K, Siahaan T J Nanotheranostics. 2025; 4(4):463-479.
PMID: 39897432 PMC: 11784990. DOI: 10.3390/jnt4040020.
Li B, Chen G, Zhong H, Li T, Lin M, Wei H Nat Commun. 2024; 15(1):10418.
PMID: 39613729 PMC: 11607351. DOI: 10.1038/s41467-024-54382-z.
Li B, Lin Y, Chen G, Cai M, Zhong H, Xiao Z Adv Sci (Weinh). 2023; 10(33):e2302134.
PMID: 37870165 PMC: 10667842. DOI: 10.1002/advs.202302134.
Drug Permeability: From the Blood-Brain Barrier to the Peripheral Nerve Barriers.
Sun Y, Zabihi M, Li Q, Li X, Kim B, Ubogu E Adv Ther (Weinh). 2023; 6(4).
PMID: 37649593 PMC: 10465108. DOI: 10.1002/adtp.202200150.